1 证券代码：002653 证券简称：海思科 公告编号：2023-053 海思科医药集团股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）《2022 年年 度报告》及其摘要已于 2023 年 4 月 18 日刊登在巨潮资讯网等公司指 定信息披露媒体。 为便于投资者进一步了解公司经营情况，公司定于 2023 年 5 月 9 日（星期二）15:00-17:00 在全景网举办 2022 年度业绩说明会，本 次业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投 资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明 会。 出席本次业绩说明会的人员有：公司董事长王俊民先生、独立董 事乐军先生、董事会秘书王萌先生、财务总监段鹏先生、保荐代表人 王正睿先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议。投资者可于 2023 年 5 月 8 日（星期一）12： ...

Revenue and Profit - The company's revenue for Q1 2023 was ¥623,643,966.44, representing a 10.97% increase compared to ¥562,010,168.13 in the same period last year[3] - Net profit attributable to shareholders was ¥28,749,239.94, up 9.72% from ¥26,203,211.37 year-on-year[3] - The total revenue for Q1 2023 was approximately ¥792.96 million, an increase from ¥630.37 million in Q1 2022, representing a growth of about 25.8%[14] - The net profit attributable to the parent company for Q1 2023 was ¥28.75 million, compared to ¥26.20 million in Q1 2022, reflecting an increase of approximately 9.7%[13] - The operating profit for Q1 2023 was ¥26.29 million, slightly up from ¥25.23 million in Q1 2022, indicating a growth of about 4.2%[12] - The total comprehensive income for Q1 2023 was ¥84.17 million, compared to a loss of ¥4.46 million in Q1 2022, marking a significant turnaround[13] Cash Flow - The net cash flow from operating activities improved significantly, totaling ¥62,064,077.64, a 174.94% increase from a negative cash flow of ¥82,814,972.24 in the same period last year[3] - The cash flow from operating activities for Q1 2023 was ¥792.96 million, significantly higher than ¥630.37 million in Q1 2022, showing a growth of about 25.8%[14] - Total cash inflow from operating activities reached ¥817,203,816.73, compared to ¥649,456,733.93 in the same period last year, reflecting a year-over-year increase of approximately 26%[15] - Cash outflow from operating activities was ¥755,139,739.09, slightly higher than ¥732,271,706.17 in Q1 2022, indicating a 3% increase[15] - The net cash flow from investing activities was -¥204,190,501.62, showing a marginal improvement from -¥204,804,378.89 in Q1 2022[15] - Cash inflow from financing activities totaled ¥896,612,751.62, a substantial increase from ¥630,381,826.12 in the previous year, marking an increase of approximately 42%[15] - The net cash flow from financing activities was ¥487,552,826.46, compared to ¥312,876,285.61 in Q1 2022, representing a growth of about 56%[15] Assets and Liabilities - Total assets as of March 31, 2023, were ¥6,479,155,437.62, reflecting a 7.17% increase from ¥6,045,955,274.42 at the end of the previous year[3] - The total current assets at the end of Q1 2023 amounted to CNY 2,396,324,149.07, up from CNY 2,053,646,749.91 at the beginning of the year, indicating an increase of about 16.7%[9] - The total liabilities decreased to CNY 2,466,085,302.22 from CNY 2,912,530,673.63, showing a reduction of about 15.3%[10] - The company's long-term equity investments rose to CNY 192,205,071.00 from CNY 185,109,765.36, reflecting an increase of approximately 3.0%[9] - The company's total non-current liabilities decreased to CNY 1,062,816,168.38 from CNY 1,423,976,752.09, indicating a reduction of approximately 25.4%[10] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 29.02%, amounting to ¥3,916,726,019.63 compared to ¥3,035,744,121.70 at the end of the previous year[3] - The total owner's equity increased to CNY 4,013,070,135.40 from CNY 3,133,424,600.79, representing a growth of about 28.1%[10] Expenses - Research and development expenses for Q1 2023 amounted to ¥91.51 million, an increase from ¥85.92 million in Q1 2022, showing a rise of approximately 6.1%[12] - The sales expenses for Q1 2023 were ¥226.65 million, compared to ¥197.36 million in Q1 2022, representing an increase of approximately 14.9%[12] - The tax expenses for Q1 2023 were ¥2.81 million, compared to ¥2.33 million in Q1 2022, indicating an increase of approximately 20.5%[12] - Payments for employee compensation increased to ¥226,144,832.28 from ¥183,123,898.94, reflecting a growth of about 23.5%[15] - Tax payments rose to ¥83,552,327.77 from ¥44,103,638.71, indicating an increase of approximately 89% year-over-year[15] Investment and Losses - The company experienced a 375.03% decrease in investment income, reporting a loss of ¥9,512,591.88 due to net losses from associates[5] - The net investment loss for Q1 2023 was ¥9.51 million, worsening from a loss of ¥2.00 million in Q1 2022[12] - The total amount of non-recurring gains and losses for the period was ¥2,721,502.80, after accounting for tax effects[4]

Financial Performance - The company's operating revenue for 2022 was CNY 3,015,294,339.82, representing an increase of 8.73% compared to CNY 2,773,314,884.86 in 2021[12]. - The net profit attributable to shareholders for 2022 was CNY 277,002,781.63, a decrease of 19.72% from CNY 345,058,649.45 in 2021[12]. - The net profit after deducting non-recurring gains and losses was CNY 95,553,398.52, which is a significant increase of 171.42% compared to CNY 35,205,086.23 in 2021[12]. - The basic earnings per share for 2022 was CNY 0.26, down 18.75% from CNY 0.32 in 2021[12]. - The total assets at the end of 2022 were CNY 6,045,955,274.42, an increase of 20.79% from CNY 5,005,285,084.31 at the end of 2021[12]. - The net assets attributable to shareholders at the end of 2022 were CNY 3,035,744,121.70, reflecting a growth of 6.82% from CNY 2,841,929,513.83 at the end of 2021[12]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of CNY 94,546,036.93, up 164.08% from CNY 35,801,459.91 in 2021[12]. - The company achieved a revenue of 3.015 billion yuan in 2022, an increase of 8.73% year-on-year, while the net profit attributable to shareholders decreased by 19.72% to 277 million yuan[36]. Market and Product Development - The company is focusing on innovation in drug development, with an increase in the number of IND and NDA applications over the past five years[19]. - The company is committed to expanding its market presence and enhancing its product offerings in response to evolving industry dynamics[19]. - The company is actively advancing the international clinical trial of its anesthetic drug HSK3486 in the United States[22]. - The company has submitted NDA for its diabetes peripheral neuropathy drug HSK16149 and type 2 diabetes treatment drug HSK7653, which are currently under review[22]. - The company is recognized as one of the top 100 Chinese pharmaceutical companies and has achieved an AAA credit rating in the pharmaceutical industry[22]. - The company is focused on providing innovative specialty drugs across various therapeutic areas, including anesthesia, oncology, and cardiovascular health[23]. - The company has established a comprehensive marketing innovation system focused on patient-centered and academic marketing, with eight major business divisions[28]. - The company has established multiple technical platforms for drug development, including platforms for poorly soluble formulations and inhalation formulations[35]. Research and Development - The company has a research and development team of over 900 personnel, with approximately 37% holding master's degrees or higher, and a high proportion of PhD holders in core departments reaching 60%[33]. - The company has undertaken 6 national-level major scientific research projects, including the clinical research of the new GABAA receptor agonist HSK3486 and innovative research on new drugs for AIDS and hepatitis B prevention[32]. - The R&D team has published nearly 40 papers in core journals, focusing on fields such as anesthesia analgesia and diabetes[32]. - The company has a strong pipeline with multiple products in various stages of clinical trials, enhancing its competitive edge[57]. - R&D investment reached approximately 958 million yuan in 2022, with expectations for further growth in 2023 to support the introduction of innovative drug products[118]. Governance and Management - The company has implemented a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and enhancing operational efficiency[86]. - The company has established independent personnel management systems and signed labor contracts with employees, ensuring no interference from controlling shareholders[88]. - The company has a diverse board with members holding positions in various other organizations, including independent directors and executives in different sectors[97][98]. - The company emphasizes a performance-based salary structure for its senior management, which is reviewed and adjusted annually[99]. - The company has established a robust governance structure with a mix of experienced professionals from various sectors, ensuring comprehensive oversight and strategic guidance[97][98]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, adhering to various environmental standards and regulations[129]. - The company achieved a total emission of 0.515 tons of particulate matter, which is below the approved limit of 3.34 tons[134]. - The company has obtained environmental impact assessment approvals for projects in Liaoning, Sichuan, and Shenyang, with specific registration numbers issued in July 2022[132]. - The company has implemented wastewater treatment measures that ensure all discharges meet or exceed local environmental standards, reflecting a commitment to sustainability[135]. - The company is actively monitoring and managing its emissions to align with regulatory requirements and improve environmental performance[136]. Social Responsibility - The company actively participated in social welfare activities, including donations to special education schools and support for frontline police officers, totaling over 10,000 yuan in various contributions[149]. - The company plans to invest 120 million yuan in a new chemical drug production base in Shannan City, Tibet, which is expected to create over 100 jobs for local farmers and students[150]. - The company provided 1,000 square meters of office space for free to support entrepreneurship for impoverished university students in Shannan City[150]. - The company emphasizes the protection of employee rights and has established a comprehensive compensation and benefits management system to ensure fair treatment and a harmonious labor relationship[149]. Future Outlook - The company plans to apply for IND for 3-4 innovative drugs, including those in oncology and analgesia fields, while also launching 5-10 new projects[77]. - The company aims to become the most trusted international pharmaceutical enterprise, focusing on "R&D + marketing" dual-driven strategy and expanding market presence with innovative drugs like HSK7653 and HSK16149[76]. - The company plans to distribute at least 20% of its distributable profits as cash dividends during profit distribution[155].